Gossamer Bio, Inc. (GOSS) posted a fourth quarter net loss of $48.1 million, or $0.21 per share, compared to a net loss of $55.8 million, or $0.59 per share, a year ago. On average, eight analysts polled by Thomson Reuters expected the company to report a loss per share of $0.21, for the quarter. Analysts' estimates typically exclude special items.
Cash, cash equivalents and marketable securities as of December 31, 2023, were $296.4 million. The company expects current cash, cash equivalents and marketable securities will be sufficient to fund operating and capital expenditures into the first half of 2026.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.